Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Department of Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK.
Immunology. 2023 Dec;170(4):470-482. doi: 10.1111/imm.13680. Epub 2023 Jul 12.
T lymphocytes play a crucial role in adaptive immunity. Dysregulation of T cell-derived inflammatory cytokine expression and loss of self-tolerance promote inflammation and tissue damage in several autoimmune/inflammatory diseases, including systemic lupus erythematosus (SLE) and psoriasis. The transcription factor cAMP responsive element modulator α (CREMα) plays a key role in the regulation of T cell homeostasis. Increased expression of CREMα is a hallmark of the T cell-mediated inflammatory diseases SLE and psoriasis. Notably, CREMα regulates the expression of effector molecules through trans-regulation and/or the co-recruitment of epigenetic modifiers, including DNA methyltransferases (DNMT3a), histone-methyltransferases (G9a) and histone acetyltransferases (p300). Thus, CREMα may be used as a biomarker for disease activity and/or target for future targeted therapeutic interventions.
T 淋巴细胞在适应性免疫中发挥着关键作用。T 细胞衍生的炎症细胞因子表达失调和自身耐受丧失会促进几种自身免疫/炎症性疾病的炎症和组织损伤，包括系统性红斑狼疮（SLE）和银屑病。环磷酸腺苷反应元件调节剂α（CREMα）在 T 细胞稳态的调节中发挥着关键作用。CREMα 的表达增加是 T 细胞介导的炎症性疾病 SLE 和银屑病的一个标志。值得注意的是，CREMα 通过反式调控和/或共募集表观遗传修饰剂，包括 DNA 甲基转移酶（DNMT3a）、组蛋白甲基转移酶（G9a）和组蛋白乙酰转移酶（p300），来调节效应分子的表达。因此，CREMα 可以作为疾病活动的生物标志物和/或未来靶向治疗干预的靶点。
